Novartis receives positive CHMP opinion for Jakavi® to treat acute and chronic graft-versus-host disease

CHMP opinion based on Phase III REACH2 and REACH3 trials that showed Jakavi improved response rates and failure-free survival compared to best available therapy1,2 Graft-versus-host disease is a... | March 25, 2022

Related Keywords

Germany ,Japan ,United States ,Canada ,Switzerland ,America ,American ,Isabella Zinck ,Susanne Schaffert ,Amy Wolf ,Nicole Zinsli Somm ,Robert Zeiser ,Samir Shah ,Parag Mahanti ,Sloan Simpson ,Alina Levchuk ,American Society Of Blood ,Twitter ,Department Of Haematology ,European Commission ,Novartis External Communications ,Lymphoma Society ,Novartis ,Exchange Commission ,University Hospital Freiburg ,European Medicines Agency ,Eu Press ,Staging Working Group ,Committee For Medicinal Products Human Use ,Novartis Hematology Communications ,Medicinal Products ,Human Use ,Medicines Agency ,Stem Cell Transplantation ,New England Journal ,England Journal ,Graft Versus Host Disease ,Host Disease ,Why Havent We Made More ,Chronic Graft Versus Host Disease ,Health Consensus Development Project ,Clinical Trials ,Blood Marrow ,Biol Blood Marrow ,Novartis Ag Stock Exchange ,News ,Information ,Press Release ,Thmp ,Opinion ,Ased ,N ,Hase ,Wii ,Reach2 ,End ,Reach3 ,Trials ,Hat ,Howed ,Kakavi ,Mproved ,Response ,Rates ,Survival ,Ompared ,O ,Pest ,Vailable ,Disease ,Ts Novn Ch0012005267 ,